



(51) International Patent Classification:

C12N 5/0783 (2010.01) C12N 15/62 (2006.01)
A61K 35/17 (2015.01) C12N 5/10 (2006.01)

(21) International Application Number:

PCT/US2023/029047

(22) International Filing Date:

28 July 2023 (28.07.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/393,787 29 July 2022 (29.07.2022) US

(71) Applicant: **ADICET THERAPEUTICS, INC.** [US/US];
1000 Bridge Parkway, Redwood City, CA 94065 (US).

(72) Inventors: **AFTAB, Blake**; c/o Adicet Therapeutics, Inc.,
1000 Bridge Parkway, Redwood City, CA 94065 (US).
BHAT, Arun; c/o Adicet Therapeutics, Inc., 1000 Bridge
Parkway, Redwood City, CA 94065 (US). **NISHIMOTO,**
Kevin; c/o Adicet Therapeutics, Inc., 1000 Bridge Park-
way, Redwood City, CA 94065 (US). **TEAGUE, Alexan-**


der; c/o Adicet Therapeutics, Inc., 1000 Bridge Parkway,
Redwood City, CA 94065 (US). **SPELTZ, Elizabeth**; c/
o Adicet Therapeutics, Inc., 1000 Bridge Parkway, Red-
wood City, CA 94065 (US). **LAMTURE, Gauri**; c/o Adicet
Therapeutics, Inc., 1000 Bridge Parkway, Redwood City,
CA 94065 (US). **DING, Beibei**; c/o Adicet Therapeutics,
Inc., 1000 Bridge Parkway, Redwood City, CA 94065 (US).
RAMADOSS, Nitya; c/o Adicet Therapeutics, Inc., 1000
Bridge Parkway, Redwood City, CA 94065 (US).

(74) Agent: **LORENZ, Todd** et al.; Squire Patton Boggs, 555
California Street, Suite 550, San Francisco, CA 94104 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

(54) Title: AFFINITY BINDING ENTITIES DIRECTED TO CD70 AND METHODS OF USE THEREOF

FIG. 1



(57) Abstract: Aspects of the disclosure include compositions and methods for the treatment of CD70-expressing tumors with engi-
neered $\gamma\delta$ T-cells. In embodiments, the $\gamma\delta$ T-cells comprise a chimeric antigen receptor (CAR) construct. The CAR construct can include
a full-length CD27 receptor domain, a costimulatory domain, an intracellular signaling domain, a combination thereof, or all thereof. The
CAR construct can contain a domain encoding for an additional polypeptide that confers advantageous functionality to the $\gamma\delta$ T- cells.

[Continued on next page]

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

- (84) Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

- (88) Date of publication of the international search report:**
04 April 2024 (04.04.2024)